Surgical resection remains the only potentially curative treatment for pancreatic ductal adenocarcinoma (PDAC). However, less than 20% of patients present with resectable disease at diagnosis due to the cancer's tendency for early local invasion and distant spread.
Even after successful resection, the majority of patients eventually relapse, which has driven intense efforts to optimize both the surgical procedure itself and the systemic therapies that accompany it. The combination of improved surgery and chemotherapy has gradually improved overall survival, though outcomes remain poor compared to many other cancers.
Adjuvant chemotherapy, delivered after surgery to eliminate residual microscopic disease, has become the cornerstone of postoperative management. The regimen modified FOLFIRINOX (mFOLFIRINOX) has emerged as the current standard based on its superior survival benefit over gemcitabine alone in the PRODIGE 24 trial.
This review summarizes the current state of surgical technique for pancreatic cancer, covering both pancreatic head resections (the Whipple procedure and its variants) and distal pancreatectomy, as well as management of vascular involvement, minimally invasive approaches, and complication management.
The standard operation for pancreatic head cancer is pancreaticoduodenectomy, which removes the pancreatic head, duodenum, common bile duct, and often the gallbladder. Achieving R0 resection (negative margins) is the primary surgical goal as positive margins are independently associated with worse survival.
The artery-first approach involves early dissection and assessment of the superior mesenteric artery (SMA) before committing to full resection. This allows the surgeon to determine resectability and margin status at the SMA, the most common site of positive margins, before completing the extensive dissection required for full pancreaticoduodenectomy.
The uncinate-first approach specifically focuses on early dissection of the uncinate process, which wraps around the SMA and superior mesenteric vein. Early uncinate dissection can improve visualization of critical vascular structures and may reduce blood loss and positive margin rates.
The triangle operation is an extended lymphadenectomy technique that removes the soft tissue triangle bounded by the SMA, celiac axis, and portal vein. This aggressive lymph node clearance aims to reduce local recurrence, though its survival benefit is still being evaluated in prospective studies.
For tumors in the body or tail of the pancreas, distal pancreatectomy with splenectomy is the standard procedure. The critical technical challenge is achieving adequate posterior and lateral margins, particularly for tumors abutting the retroperitoneal soft tissue and major vessels.
RAMPS (Radical Antegrade Modular Pancreatosplenectomy) is a technique for distal pancreatectomy that follows oncological principles by dissecting along predetermined anatomical planes to achieve wider posterior margins. By proceeding in an antegrade (left to right) direction along the anterior surface of Gerota's fascia, RAMPS aims to improve R0 resection rates.
DP-CAR (Distal Pancreatectomy with Celiac Axis Resection), also known as the Appleby procedure, is used for tumors of the pancreatic body that involve the celiac artery. This technically demanding operation sacrifices the celiac axis while relying on collateral blood flow via the gastroduodenal artery to maintain perfusion of the liver, stomach, and spleen.
Venous resection of the portal vein or superior mesenteric vein is well established when tumor involvement is limited to these vessels. Arterial resection of the SMA or celiac axis is more controversial and typically reserved for specialized centers with high case volumes and selected patients who might otherwise be denied resection.
Laparoscopic and robotic pancreatic resections have been increasing in adoption, driven by the well-established benefits of minimally invasive surgery for other abdominal cancers, including reduced blood loss, shorter hospital stay, and faster recovery to start adjuvant chemotherapy.
For distal pancreatectomy, laparoscopic approaches are now widely considered safe and oncologically equivalent to open surgery based on multiple comparative studies. The LEOPARD randomized controlled trial demonstrated that laparoscopic distal pancreatectomy had significantly faster functional recovery than open surgery.
Minimally invasive pancreaticoduodenectomy is more technically complex and its oncological equivalence to open surgery is still being established. The robotic platform may offer advantages for the intricate anastomoses required during reconstruction, though evidence from randomized trials is still maturing.
Patient selection is critical for minimally invasive approaches: factors such as tumor size, body habitus, vascular involvement, and prior abdominal surgery all influence whether a laparoscopic or robotic approach is feasible and safe for a given patient.
Pancreatic surgery carries significant perioperative risk. Beyond postoperative pancreatic fistula, common complications include delayed gastric emptying, postpancreatectomy hemorrhage, bile leak, and wound infection. Effective complication management is essential to ensuring patients can receive adjuvant therapy on schedule.
Perioperative protocols such as enhanced recovery after surgery (ERAS) programs have been adopted at many centers to standardize preoperative preparation, anesthetic management, and postoperative care. ERAS protocols consistently reduce length of hospital stay and may reduce complication rates.
When complications do occur, interventional radiology (IR) plays an increasing role in managing them without reoperation. Percutaneous drainage of fluid collections, embolization for postoperative hemorrhage, and endoscopic management of biliary leaks are all now preferred over surgical re-exploration in most cases.
Volume-outcome relationships are strong in pancreatic surgery: high-volume centers and surgeons achieve consistently lower mortality, complication rates, and better long-term outcomes than low-volume practices. This supports the ongoing trend toward centralization of pancreatic surgery to specialized centers.
The field is moving toward more personalized surgical decision-making guided by molecular profiling, improved imaging, and predictive biomarkers. Identifying which patients will truly benefit from aggressive resection, including arterial resection or extended lymphadenectomy, remains a key research question.
Neoadjuvant therapy, given before surgery to downstage tumors and select patients who respond favorably, is increasingly being studied as an alternative or complement to upfront resection. Early data suggest neoadjuvant FOLFIRINOX may improve R0 rates and survival in borderline resectable patients.
Integration of intraoperative technologies such as fluorescence-guided surgery, intraoperative ultrasound, and rapid margin assessment techniques may further improve R0 resection rates and reduce the need for reoperation due to positive margins.
Ultimately, the best outcomes for pancreatic cancer patients will come from tight integration between surgical excellence and optimal systemic therapy, reinforcing the importance of multidisciplinary teams in planning and executing treatment for every patient with potentially resectable disease.